Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul 5:10:923797.
doi: 10.3389/fpubh.2022.923797. eCollection 2022.

Lipoprotein(a) in Cardiovascular Diseases: Insight From a Bibliometric Study

David Šuran  1   2 , Helena Blažun Vošner  3   4   5 , Jernej Završnik  3   5 , Peter Kokol  2   6 , Andreja Sinkovič  2   7 , Vojko Kanič  1   2 , Marko Kokol  6   8 , Franjo Naji  1   2 , Tadej Završnik  1   2
Affiliations
Review

Lipoprotein(a) in Cardiovascular Diseases: Insight From a Bibliometric Study

David Šuran et al. Front Public Health. .

Abstract

Lipoprotein(a) [Lp(a)] is a complex polymorphic lipoprotein comprised of a low-density lipoprotein particle with one molecule of apolipoprotein B100 and an additional apolipoprotein(a) connected through a disulfide bond. The serum concentration is mostly genetically determined and only modestly influenced by diet and other lifestyle modifications. In recent years it has garnered increasing attention due to its causal role in pre-mature atherosclerotic cardiovascular disease and calcific aortic valve stenosis, while novel effective therapeutic options are emerging [apolipoprotein(a) antisense oligonucleotides and ribonucleic acid interference therapy]. Bibliometric descriptive analysis and mapping of the research literature were made using Scopus built-in services. We focused on the distribution of documents, literature production dynamics, most prolific source titles, institutions, and countries. Additionally, we identified historical and influential papers using Reference Publication Year Spectrography (RPYS) and the CRExplorer software. An analysis of author keywords showed that Lp(a) was most intensively studied regarding inflammation, atherosclerosis, cardiovascular risk assessment, treatment options, and hormonal changes in post-menopausal women. The results provide a comprehensive view of the current Lp(a)-related literature with a specific interest in its role in calcific aortic valve stenosis and potential emerging pharmacological interventions. It will help the reader understand broader aspects of Lp(a) research and its translation into clinical practice.

Keywords: atherosclerosis; bibliometrics; calcific aortic valve stenosis; cardiovascular disease; inflammation; lipoprotein(a); post-menopausal women; synthetic knowledge synthesis.

PubMed Disclaimer

Conflict of interest statement

MK was employed by Semantika Research, Semantika d.o.o. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Trend in the number of articles.
Figure 2
Figure 2
The spectrogram of the lipoprotein(a) research literature production.
Figure 3
Figure 3
Country Co-operation network based on Co-authorships between 30 most productive countries.
Figure 4
Figure 4
Author keywords (with 20 or more occurrences) cluster landscape. Author keywords cluster landscape revealed five research themes: Lp(a) and inflammation (violet), Lp(a) cardiovascular diseases (blue), Lp(a) in women (yellow), prevention and treatment of coronary artery disease in diabetic patients (green), lipid abnormalities and treatment (red).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Boffa MB, Koschinsky ML. Oxidized phospholipids as a unifying theory for lipoprotein (a) and cardiovascular disease. Nat Rev Cardiol. (2019) 16:305–18. 10.1038/s41569-018-0153-2 - DOI - PubMed
    1. Wu MF, Xu KZ, Guo YG, Yu J, Wu Y, Lin LM. Lipoprotein(a) and atherosclerotic cardiovascular disease: current understanding and future perspectives. Cardiovasc Drugs Ther. (2019) 33:739–48. 10.1007/s10557-019-06906-9 - DOI - PubMed
    1. Saeed A, Virani SS. Lipoprotein(a) and cardiovascular disease: current state and future directions for an enigmatic lipoprotein. Front Biosci. (2018) 23:1099–112. 10.2741/4635 - DOI - PubMed
    1. Tada H, Nohara A, Inazu A, Mabuchi H, Kawashiri M-A. Remnant lipoproteins and atherosclerotic cardiovascular disease. Clin Chim Acta. (2019) 490:1–5. 10.1016/j.cca.2018.12.014 - DOI - PubMed
    1. Tsimikas S. A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol. (2017) 69:692–711. 10.1016/j.jacc.2016.11.042 - DOI - PubMed

Supplementary concepts